Triple-action diabetes jab cuts blood sugar and body weight, study shows

Diabetes and obesity have become inseparable health conversations of the past decade, with GLP-1 drugs like Ozempic and Mounjaro embodying that overlap. The Guardian reports that a new weekly injection takes the next step by targeting three hormone pathways at once, and the early data presented at the American Diabetes Association meeting show it outperforms current treatments on both blood sugar and body weight.

According to the Guardian, the drug works on the receptors of three different gut and pancreatic hormones simultaneously: GLP-1, GIP and glucagon. The combination is designed to boost insulin secretion after meals while also raising energy expenditure and suppressing appetite. Previous-generation GLP-1 drugs hit only one hormone, second-generation drugs targeted two, and this triple-action approach is designed to deliver a stronger biological signal.

Most trial participants had type 2 diabetes and obesity. The Guardian reports that patients on the new injection lost a significant proportion of their body weight over roughly a year and saw their HbA1c — the standard measure of blood-sugar control — drop substantially. Compared with single-hormone GLP-1 treatments, the triple-action injection produced larger effects, and produced them faster.

The Guardian writes that the safety profile was also evaluated. The most common side effects were nausea, vomiting and diarrhoea, the classic burdens of the GLP-1 class, and most patients managed them with dose titration. The rate of discontinuation for severe side effects was similar to that of older single-hormone regimens, suggesting the more powerful effect did not come at a sharply higher tolerance cost.

The data presented at the conference, as the paper reports, did not stop at type 2 diabetes patients. Phase 3 trials are underway in obese but non-diabetic adults, and the Guardian writes that the first results are expected within the next twelve months. If those results are positive, a new category in standalone obesity treatment could open.

The Guardian emphasised that the question of access will matter as much as clinical benefit. NHS reimbursement of GLP-1 drugs has been a tense issue in the UK; their monthly cost and the size of the eligible patient population have put the system under pressure. The new triple-action injection is expected to be priced comparably highly, and NICE deliberations on price and reimbursement may be tougher than usual.

Experts describe the drug as carrying "game-changing" potential in the diabetes market. A diabetologist quoted by the Guardian said that "hitting three hormones at once was a hypothesis ten years ago; now we can measure its clinical effect". Such reactions suggest the drug is seen not just as another alternative but as a step that could reshape the standard treatment ladder.

Long-term safety questions remain, the Guardian notes. Effects on the pancreas, thyroid and gallbladder continue to be monitored; rare side effects associated with older GLP-1 drugs need to be tracked in longer follow-up studies of the new triple-action treatment. The paper reports that the manufacturer plans to collect global real-world data over the coming years.

From the patient perspective, the Guardian also shared lifestyle changes reported by trial participants. One patient diagnosed with type 2 diabetes years ago and using the injection for several months told the paper that "a single weekly injection regulates my blood sugar and my weight is coming down; I no longer feel the need to snack after meals". Such accounts illustrate how the numerical data feels in daily life.

The broader message the Guardian conveys is that the past decade has been one of the most rapid waves of innovation in diabetes and obesity care. From single-hormone GLP-1 through dual-hormone Mounjaro to the new triple candidates, the pace, the Guardian summarises, is "multiplying the clinical effect, but also amplifying questions about access and cost".